The FDA will no longer regularly ask for two pivotal studies to support approval of novel drugs, Commissioner MARTIN MAKARY and top deputy VINAY PRASAD wrote in a medical journal article. They announced that one adequate and well-controlled trial, together with confirmatory evidence, will be the agency’s “default standard.” The new policy, which Makary previously signaled was forthcoming, is thin on some details, however.
By Amanda Conti and Ned Pagliarulo | Feb 19, 2026 6:47 PM EST
Catching up: Makary’s hints at policy change
- In December 2025, FDA Commissioner MARTIN MAKARY told STAT that he planned to make a single pivotal trial the agency’s default option for drug approvals, shifting its longtime two-trial standard. “You can achieve the same statistical power with one trial as you would with two trials when it’s designed and controlled appropriately,” Makary said in his interview with the publication. [Read AgencyIQ’s initial analysis of the plan here.]
- This change reportedly contributed to tensions between former Center for Drug Evaluation and Research Director RICHARD PAZDUR and Makary, The Washington Post reported on Nov. 21. “Pazdur and Makary have disagreed over the commissioner’s plan to reduce the number of research studies needed to justify more drug-related decisions, such as changes to drug labels,” two people granted anonymity told the Post. “Makary has argued that his plan to reduce the burden of proof to a single study would allow the agency to more quickly respond to new evidence. Pazdur has countered that multiple studies may be necessary in many cases and would better protect public health.” Subsequent reporting by the Post indicated that this clash, among others, contributed to Pazdur’s decision to retire weeks after taking the CDER director job.
- Makary referenced the policy change again in a January 2026 interview on the All-In podcast. “I had one pharma executive tell me, ‘Hey, I love you’re going from two to one pivotal trials. That means we can run twice as many drugs through large pivotal trials,’” Makary said. “That’s what we want. We want to see more.” He later contextualized the policy as helping address the long development times required to bring a new drug to market, which he said “makes no sense” today.
- The FDA has advanced other policies in parallel that could align with a one-trial standard. The agency in January released draft guidance on the use of Bayesian methodology in clinical research, which could help sponsors more easily design the kind of adaptive or seamless trials that may be favored under a one-trial standard. Makary has also repeatedly hinted that a major new proposal on these study types is in the works. [Read AgencyIQ’s analysis of the Bayesian guidance here and of Makary’s plans for seamless trials here.]
Context: The FDA’s evidence standards in principle and practice
- When seeking approval from the FDA, companies must demonstrate “substantial evidence,” as defined by the Federal Food, Drug, and Cosmetic Act, that their product is safe and effective. Traditionally, the FDA has interpreted “well-controlled investigations” to mean at least two clinical trials for applications for new drugs or supplemental indications.
- With the help of litigation and legislation, the legal definition has been updated so that “one adequate and well-controlled investigation” can be sufficient to demonstrate safety and effectiveness if supported by “confirmatory evidence.” The decision to accept two trials or a single trial with confirmatory evidence belongs to the FDA, though statute directs the agency to “implement a structured risk-benefit assessment framework.” The FDA has published and revised guidance offering its perspective on both foundational issues (last updated in December 2019) and the types of confirmatory evidence it is willing to consider (last updated in September 2023). The second guidance document states that, in general, the volume of confirmatory evidence needed is inversely proportional to the strength of the single adequate and well-controlled study. [Read full AgencyIQ analysis here.] Both documents currently remain in draft form.
- Over time, the FDA has increasingly accepted a single pivotal trial and confirmatory evidence to support novel drug approvals. In a July 2024 analysis of original labeling documents, AgencyIQ found that the majority of new molecular entities approved by the agency since 2020 relied on a single pivotal trial. While the median number of pivotal trials held steady at two until 2020, the median has since dropped to one. AgencyIQ’s most recent analysis found that 27 of 46, or 59%, of novel products approved in 2025 listed just one pivotal clinical trial in their original labeling.
The FDA’s new bar for drug approval
- The FDA will make one pivotal trial its “default standard” for approval of new medicines, Makary and Center for Biologics Evaluation and Research Director VINAY PRASAD declared in a “Sounding Board” piece published by The New England Journal of Medicine on Feb. 18, 2026. “Going forward, the FDA’s default position is that one adequate and well-controlled study, combined with confirmatory evidence, will serve as the basis of marketing authorization of novel products,” they wrote. While they acknowledged that the agency has often granted approvals on a similar basis in the past, they argued that “there remains confusion from manufacturers regarding settings in which a single trial will be accepted.”
- Prasad and Makary justified this change by pointing to the many ways modern drug development can establish the “clinical credibility” of an experimental drug. They compared the current moment in clinical science to decades past, when two trials were necessary to reduce the risk of obtaining a lucky false positive with an ineffective or inert compound. “Yet in the modern world, as drug discovery becomes increasingly precise and scientific, the FDA considers not just effects on survival, but biochemical and intermediate changes that tell a complete biologic story: does this drug actually work?” Prasad and Makary wrote. “In this setting, overreliance on two trials no longer makes sense.” They outlined a list of other factors that the FDA will scrutinize to assess clinical credibility, including a trial’s control group, endpoints and statistical power, as well as the resulting data’s “concordance with biologic correlates” and “alignment” with intermediate endpoints.
- Many of the factors they listed are already points of focus for FDA reviewers assessing submissions based on two trials. However, the way Prasad and Makary presented them in NEJM suggests that they could push the agency to apply higher standards on one trial. For instance, in noting how a trial’s control arm can contribute to a drug’s clinical credibility, they suggested that the FDA wants to see sponsors use the best available treatment as a comparator and concurrent controls instead of historical controls. Another factor they listed is “whether post-protocol therapy is on par with the U.S. standard of care,” citing a 2023 paper Prasad coauthored that criticized the use of “substandard” post-progression treatment in many cancer drug trials and called for stricter regulatory rules. Later in the NEJM piece, Prasad and Makary added that their proposal “may even enhance the FDA’s standards and reduce the risk of approval of products that may later need to be withdrawn, since greater attention will be placed on the one trial.” As an example, they noted that some past FDA approvals were based on trials comparing novel drugs to controls “no longer used by the American people,” again citing a prior paper coauthored by Prasad. The FDA’s focus moving forward, in other words, seems to be on trial quality rather than trial quantity.
- Bayesian statistics can help capture many of these clinical factors, Prasad and Makary wrote. The FDA’s draft guidance, which is currently out for comment, details how sponsors should structure Bayesian trial analyses, with a particular note on controlling the Type 1, or false positive, rate. This is done differently under Bayesian methodology than the “frequentist” approach historically been most used in drug trials, requiring careful planning on the part of sponsors. In a world in which the FDA requires only one pivotal study, sponsors’ statistical assumptions may get a closer look by reviewers who lack a second study to provide reassurance on Type 1 error control.
- The FDA may still ask sponsors for two trials. “If an intervention has a nebulous, pluripotent or nonspecific mechanism of action; if it affects a labile, short-term, or surrogate outcome; or if a trial has some underlying limitation or deficiency,” Prasad and Makary wrote, “additional adequate and well-controlled studies may be required.” While previously, sponsors were expected to justify why a single trial was sufficient, the agency’s leaders are now indicating that the FDA will tell them when it’s not. The outlined criteria are specific, but they’re also subject to interpretation. The FDA’s view of a trial limitation or the durability of a drug’s effect may be different than a sponsor’s, for instance. Also left undescribed is when the FDA might communicate whether additional studies are necessary.
- “This reform is being rolled out synchronously with the agency’s postmarket initiative to collect robust data on all drugs and devices,” Prasad and Makary wrote. In a June 2025 JAMA Viewpoint article that defined their joint regulatory philosophy, the duo previously argued that the infrastructure to support regulatory use of large, heterogeneous data sources should be expanded to enhance postapproval monitoring and adverse event reporting. “Current systems both wrongly condemn and wrongly exonerate medical products,” Makary and Prasad wrote. [Read the full AgencyIQ breakdown of the piece here.] An October contract notice then previewed plans to enhance and expand the FDA’s existing postmarket surveillance system, the Sentinel Initiative, consolidating systems for drugs, biologics and devices into a centralized framework. However, the status of this project remains unclear, and the agency recently indicated in user fee negotiations that it is not looking to significantly expand Sentinel’s capabilities to include medical devices. [Read AgencyIQ’s January 2026 deep dive on Sentinel here.] Recent meeting minutes from negotiations for the medical device user fee program reauthorization do indicate a larger role for the device-specific surveillance system, known as the National Evaluation System for Health Technology, or NEST, but primarily as an evidence-generation mechanism rather than for surveillance. A September 2025 contract notice separately outlined an entirely new adverse event monitoring system – called “FDA Adverse Event Management (AEM)” in the notice – that would “centralize” and potentially replace the agency’s existing product-specific safety surveillance systems. However, the notice showed that the proposal was still in planning. Prasad and Makary’s reference in NEJM to a synchronous rollout, therefore, raises questions regarding how “robust data on all drugs and devices” will be collected and by whom.
- Makary and Prasad defended their proposal against expected criticism. They denied that the FDA “is relaxing its standards and will now permit ineffective or even harmful products on the U.S. market,” arguing that “the FDA has never been perfect” and that multiple trials can still produce erroneous conclusions if there are deficiencies in trial design. The leaders added that increased attention on one trial could enhance standards, especially because FDA reviewers may have more time to assess an individual protocol.
- The authors also addressed skepticism that the proposal’s impact could be limited given the agency’s consistent and increasing acceptance of these approaches in recent years – a point previously raised by AgencyIQ. “A wide body of literature suggests that default options anchor individuals and institutions psychologically, and we believe that formally articulating the FDA’s new position will spur biomedical innovation,” Makary and Prasad wrote, citing DANIEL KAHNEMAN’s popular 2011 psychology book, Thinking, Fast and Slow. This reference stands apart from other sources cited in the article, which mostly consist of research articles (the majority of which feature Prasad as an author).
- Throughout the article, Makary and Prasad outlined their expectations for the announcement’s benefits. “Our move to change the FDA’s default position from two clinical trials to one will substantially reduce costs for sponsors and will speed drugs to market,” they wrote. Citing a March 2025 paper Prasad coauthored, they estimated that a single pivotal study could cost “30 million to 150 million dollars.” The 2025 paper references a 2020 paper reporting a study that found significant variation in costs associated with trials, noting, “From an individual clinical trial perspective, the largest single influence on estimated cost was the number of patients needed to establish the treatment effects.” Industry has historically cited much higher costs for drug development than Prasad’s research; recent studies have produced widely divergent estimates.
What’s next?
- “The FDA expects a surge in drug development in response to our initiative,” Prasad and Makary concluded. How should sponsors respond? In the short term, the new policy creates additional regulatory uncertainty just as the agency is under fire for a perceived lack of predictability. For the roughly 55% to 70% of novel products already consistently approved based on one trial and confirmatory evidence, how will increased scrutiny of design aspects such as control and endpoint selection play out? For the roughly 30% to 45% of novel products generally approved based on multiple trials, what proportion will have the opportunity to leverage the new default setting? Will the new standard be applied consistently across review centers and divisions? This uncertainty is particularly pronounced for sponsors currently in the middle of development. Could the new policy lead to course changes or scrapped second trials?
- Still, if successfully implemented, the one-trial default could meaningfully lower the cost and time of development for some sponsors. In notes published after the NEJM piece was released, equity analysts covering the industry highlighted drug developers that could benefit, including companies working in psychiatry, immunology and cardiology – fields that have historically seen fewer drugs approved based on a single trial. But the specifics matter. A more stringent singular trial may be more expensive or lengthy than two that are less rigorous. In CAR-T cell therapy, for example, Prasad recently outlined a new approach to approving new products that demands randomized evidence proving superiority on time-to-event endpoints. All seven currently licensed CAR-T therapies won approval based on single-arm studies that, for six of the seven, measured response rates for the primary endpoint.
- The policy shift comes after Prasad reportedly overruled agency staff and refused review of an experimental influenza vaccine developed by Moderna. In a refuse-to-file letter published by the biotechnology company, Prasad cited Moderna’s choice of control in a large efficacy study that enrolled nearly 41,000 volunteers. The licensed, standard-dose flu shot Moderna used as a comparator “does not reflect the best-available standard of care in the United States at the time of study,” Prasad wrote. Citing prior FDA communication, Moderna countered that the regulator had previously signed off on its trial plans. [Read AgencyIQ’s full analysis of the back-and-forth here.] While the agency reversed course on Feb. 18 and agreed to review Moderna’s submission, the episode raised questions about whether sponsors can rely on FDA feedback remaining consistent. It also showed how study design issues can trip up sponsors even when their principal trial otherwise appears robust. Both points are likely to be top of mind for sponsors deciding how to act on the FDA’s new policy.
- The NEJM piece is another example of FDA leadership issuing high-profile policy changes through podcasts and medical literature rather than traditional channels. In addition to gaps in practical information, this format has important implications for the staying power of the announced changes. To implement this change, the agency will likely need to issue revisions or finalize the two draft guidance documents pertaining to foundational issues and confirmatory evidence. The term “substantial evidence” also appears in dozens of guidance documents, indicating that adjusting the threshold for meeting this standard could have wide-ranging implications. Until such steps are taken, it’s fair to ask whether sponsors will be comfortable basing development decisions on a three-page paper written by embattled senior leaders.
- The article does not offer any plans to formally evaluate the policy change. Novel product applications currently under review or poised to be submitted in the next year reflect conversations and planning under the previous trial paradigm and years of drug development. This means that it may take a few years for any new trends to surface – a timeline that could outlast the tenure of the authors.
Featuring additional research by Laura DiAngelo and previous research from Alexander Gaffney.
To contact the authors of this item, please email Amanda Conti ( aconti@agencyiq.com) or Ned Pagliarulo ( npagliarulo@agencyiq.com).
To contact the editor of this item, please email Jason Wermers ( jwermers@agencyiq.com).
Key documents and dates